Shanghai - Delayed Quote CNY

Yifeng Pharmacy Chain Co., Ltd. (603939.SS)

Compare
26.34
+0.45
+(1.74%)
At close: April 3 at 3:00:03 PM GMT+8
Loading Chart for 603939.SS
  • Previous Close 25.89
  • Open 25.67
  • Bid 26.34 x --
  • Ask 26.35 x --
  • Day's Range 25.60 - 26.50
  • 52 Week Range 17.56 - 44.80
  • Volume 6,485,431
  • Avg. Volume 6,915,383
  • Market Cap (intraday) 31.935B
  • Beta (5Y Monthly) 0.56
  • PE Ratio (TTM) 20.90
  • EPS (TTM) 1.26
  • Earnings Date --
  • Forward Dividend & Yield 0.75 (2.85%)
  • Ex-Dividend Date Oct 15, 2024
  • 1y Target Est --

Yifeng Pharmacy Chain Co., Ltd. engages in the retail of pharmaceutical products in China. It also offers Western and Chinese patent medicine, traditional Chinese medicine herbal pieces, medical devices, health supplements, personal care products, and convenience products related to health. The company operates pharmaceutical chain stores in Hunan, Hubei, Shanghai, Jiangsu, Jiangxi, Zhejiang, Guangdong, Hebei, Beijing, and Tianjin. Yifeng Pharmacy Chain Co., Ltd. was founded in 2001 and is headquartered in Changsha, China.

www.yfdyf.cn

39,652

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 603939.SS

View More

Performance Overview: 603939.SS

Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

603939.SS
9.16%
SSE Composite Index (000001.SS)
0.29%

1-Year Return

603939.SS
32.94%
SSE Composite Index (000001.SS)
8.89%

3-Year Return

603939.SS
2.61%
SSE Composite Index (000001.SS)
1.81%

5-Year Return

603939.SS
26.88%
SSE Composite Index (000001.SS)
20.91%

Compare To: 603939.SS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 603939.SS

View More

Valuation Measures

Annual
As of 4/3/2025
  • Market Cap

    31.39B

  • Enterprise Value

    28.88B

  • Trailing P/E

    20.96

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.34

  • Price/Book (mrq)

    3.11

  • Enterprise Value/Revenue

    1.23

  • Enterprise Value/EBITDA

    12.54

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.37%

  • Return on Assets (ttm)

    5.48%

  • Return on Equity (ttm)

    15.79%

  • Revenue (ttm)

    23.92B

  • Net Income Avi to Common (ttm)

    1.52B

  • Diluted EPS (ttm)

    1.26

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.06B

  • Total Debt/Equity (mrq)

    50.92%

  • Levered Free Cash Flow (ttm)

    4.05B

Research Analysis: 603939.SS

View More

Company Insights: 603939.SS

Research Reports: 603939.SS

View More

People Also Watch